The short version
MEDVi is a Los Angeles-based telehealth company that grew from roughly $20,000 in startup capital to more than $400 million in 2025 GLP-1 revenue, largely by running an AI-powered social media marketing operation at unprecedented scale. In April 2026 the company was the subject of a high-profile New York Times profile framing it as a proof-of-concept for a one-founder billion-dollar company.
But six weeks before that profile ran, the FDA sent MEDVi a formal warning letter for misbranding its compounded GLP-1 products. A class-action lawsuit is pending against its clinical infrastructure partner. And a data breach at that same partner exposed roughly 1.6 million patient records in January 2026. These are not historical issues — they are active regulatory and legal matters as of this writing.
If you are researching MEDVi because you want the cheapest oral GLP-1 option, this review exists to give you context the marketing will not. MEDVi is not our recommended pick — not because compounded GLP-1 is categorically unsafe, but because you can access safer, better-documented programs at comparable or lower cost.
This review is an independent editorial assessment. It contains affiliate links to alternative providers we do recommend. We have no financial relationship with MEDVi. Compounded medications are not FDA-approved as finished products.
The FDA warning letter, explained
On February 20, 2026, the Center for Drug Evaluation and Research issued warning letter #721455 to MEDVi, LLC. The letter was one of dozens the FDA sent to telehealth companies marketing compounded semaglutide and tirzepatide that month — an industry-wide enforcement action, not a targeted investigation.
The letter identified two distinct categories of violation:
1. Misbranding through misleading labeling
The FDA found that product images on the MEDVi website depicted vials and packaging bearing the MEDVi name, suggesting MEDVi itself was the drug compounder. In fact, MEDVi does not compound medications — that work is done by separate licensed pharmacies. Under 21 CFR § 201.1(h)(2), placing a name on a drug label without qualification represents that the named entity is the sole manufacturer. When that representation is false, the product is misbranded.
2. Misbranding through claims implying FDA approval
The second violation involved marketing language on the site that, in the FDA's reading, suggested the compounded products had been FDA-approved or evaluated for safety and effectiveness. Compounded medications are prepared by licensed pharmacies for individual patients and are not approved as finished products. Any marketing that implies otherwise is, by FDA standards, false or misleading.
An FDA warning letter is a formal notice of alleged violations, not a finding of guilt. The recipient has 15 working days to respond in writing with specific corrective actions. Failure to respond can lead to seizure, injunction, or additional enforcement. Warning letters are publicly searchable at fda.gov.
The OpenLoop breach and the pending class action
MEDVi does not employ its own clinicians for most patient encounters. Instead, it contracts with OpenLoop Health, a clinical infrastructure platform that supplies telehealth providers with access to licensed practitioners. This arrangement is common in the telehealth industry. It also means that OpenLoop's operational and legal issues flow downstream to MEDVi's patients.
In January 2026, OpenLoop Health disclosed a cybersecurity incident. Public reporting indicates that approximately 1.6 million patient records were exposed. The breach has triggered multiple class-action complaints as of this writing.
A separate class-action complaint, Day v. OpenLoop Health (Case 1:25-cv-01418, filed in the U.S. District Court for the District of Delaware on November 20, 2025), raises questions about the clinical and scientific basis for marketing compounded oral tirzepatide tablets. Tirzepatide is a 4,813-dalton peptide molecule; the complaint alleges that there is no published human pharmacokinetic data supporting meaningful oral absorption of the intact peptide. Eli Lilly, which holds the patents on injectable tirzepatide, developed a different molecule entirely (orforglipron, now sold as Foundayo) when it wanted a daily oral GLP-1 — because the peptide form does not work as a tablet.
This is a live case with no verdict. Describing the allegations is not the same as predicting the outcome. But the underlying scientific question — whether compounded oral tirzepatide has any viable absorption pathway — is real.
What MEDVi actually sells
MEDVi's GLP-1 product line consists of compounded semaglutide and compounded tirzepatide, delivered as either injections or oral formulations depending on the program tier. The company positions its pricing aggressively — often below the industry mean — and relies on high-volume, algorithmically-targeted Facebook and Instagram advertising to drive intake.
The marketing side of the business has drawn its own scrutiny. Investigative reporting by Futurism identified 800+ Facebook pages tied to MEDVi using AI-generated doctor profile photos and synthetic "before and after" weight-loss images. The synthetic image use was acknowledged in subsequent reporting but raises the question of whether consumers who saw those ads understood they were looking at AI-generated content rather than real patient outcomes.
Pricing breakdown (verify current terms)
| Product tier | Starting price | Notes |
|---|---|---|
| Compounded semaglutide (injection) | $179/mo | Introductory; steps up to $299/mo at higher doses |
| Compounded tirzepatide (injection) | $279/mo | Introductory; steps up to $399/mo at higher doses |
| Compounded oral formats | Varies | Tablet, ODT, or sublingual depending on pharmacy |
Prices are billed on recurring cycles and are typically non-refundable once processed. Verify current pricing and cancellation terms on the MEDVi website before enrolling, as pricing structure has changed multiple times in 2026.
What MEDVi does well
Strengths
- Aggressive starter pricing at $179/mo for compounded semaglutide
- Fast intake and prescription decisions (often within 24–48 hours)
- Both injection and oral formulations available
- Consumer-friendly website and mobile experience
Serious concerns
- Active FDA warning letter (February 2026) for misbranding
- OpenLoop clinical partner disclosed January 2026 data breach
- Pending Delaware class action on oral tirzepatide science
- AI-generated "doctor" profiles and synthetic before-after imagery in marketing
- No published third-party clinical quality audit
- Limited transparency on which compounding pharmacy fills your script
Safer alternatives we recommend instead
If you are specifically looking for a legitimate path to an oral GLP-1 medication, there are two providers we recommend over MEDVi — not because they are the cheapest, but because they have the transparency and regulatory standing MEDVi does not.
Sesame Care — brand-name path
Sesame Care is a Novo Nordisk Recognized Care Provider. Through Sesame you can get a clinician consultation and a prescription for FDA-approved brand-name Wegovy pill, Rybelsus, or Foundayo — not compounded alternatives. This is the cleanest, safest path for most people starting an oral GLP-1 in 2026.
SHED — if you are going compounded anyway
If you have decided on compounded for budget reasons, SHED is the best-documented option we have reviewed. LegitScript-certified, no warning letters, widest format variety (tablet, ODT, lozenge), and transparent disclosure of which 503A compounding pharmacy fills each prescription. Compounded medications are not FDA-approved.
Bottom line
MEDVi is a fast-moving company generating enormous revenue — but in April 2026, its regulatory, operational, and clinical partner situation has accumulated more unresolved issues than any other telehealth GLP-1 provider we track. The warning letter, the class action, the data breach, and the questions about oral tirzepatide science are all independently concerning. Together, they make MEDVi an outlier among compounded GLP-1 providers.
There are better options at comparable cost. Start with Sesame Care for the brand-name path. If you have specific reasons to prefer compounded, SHED is the more transparent, better-regulated choice.
Is MEDVi shutting down?
No, MEDVi is still operating as of April 2026. The FDA warning letter does not shut down a company — it requires a written corrective response within 15 working days and ongoing compliance. Whether MEDVi's response satisfies the FDA is not yet publicly known.
Is the medication itself unsafe?
The FDA warning letter addressed marketing and labeling, not the pharmaceutical quality of the drugs. However, because MEDVi does not publicly disclose which compounding pharmacy fills each prescription, it is difficult for a patient to independently verify the source of their medication.
What happens to my prescription if MEDVi stops offering GLP-1s?
Your prescription would need to be transferred to another provider. Starting fresh with a Novo Nordisk Recognized Care Provider like Sesame Care or a LegitScript-certified compounded provider like SHED is straightforward and gives you a cleaner paper trail from the beginning.
Should I be worried about the OpenLoop data breach?
If you have enrolled with MEDVi or another OpenLoop-affiliated provider, you can check whether your records were affected by monitoring the notification letters OpenLoop has been sending to affected patients. The breach disclosure is public; specific affected-individual notification is how patients confirm exposure.